KB-1264

Urelumab

52688

Home » Urelumab

Background of Urelumab

CD137 is a costimulatory member of the TNF receptor superfamily that is expressed on a variety of immune cells following activation, including T cells, dendritic cells, and natural killer cells. Urelumab (BMS-663513, Bristol-Myers Squibb) is an agonist, fully human mAb, engineered as an IgG4 to reduce binding to Fc receptors with a hinge mutation (S228P) to improve stability. In preclinical studies, urelumab enhanced IFNγproduction, T-cell survival, and the cytolytic activity of antigen-specific T cells, as expected for an antibody with costimulatory activity.

Specifications

Catalog Number	KB-1264
Antibody Name	Urelumab
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	CD137
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Sznol M, Hodi FS, Margolin K, McDermott D, Ernstoff M, Kirkwood J, et al Phase I/II study of BMS-663513, a fully-human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. J Clin Oncol 2008; 26:15s(suppl; abstr 3007).
Jure-Kunkel MN, Calarota S, Girit E, Abraham R, Balimane P, Price K, et al Functional characterization of fully human anti-CD137 antibodies. In:Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1–5; Washington, DC. Philadelphia, PA: AACR; 2006. Abstract nr 4759.
Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012; 61:1721–33.